Evommune (EVMN) begins NYSE trading after pricing a US$ 150 m IPO — a key test of appetite for inflammation and immunology assets.

Halozyme’s US$ 1.3 b convertible-note offering may gauge investor confidence in large-cap biotech credit.

Follow potential post-earnings momentum from Charles River and Bio-Techne as investors rotate into services and supplies.

Bio-Techne Corp. (NASDAQ: TECH) reported Q1 FY2026 net sales of US$ 286.6 m (-1 % YoY), missing consensus of ~US$ 291.2 m. Diagnostics and spatial biology declined 4 % to US$ 79.5 m, as management cited soft research spending and delayed recovery in biotech end-markets. 👉 Read more

Charles River Laboratories (NYSE: CRL) beat Q3 expectations with adjusted EPS US$ 2.43 (vs ~US$ 2.34 expected) and raised 2025 guidance to US$ 10.10–10.30. The company highlighted stabilizing biotech demand and ongoing US$ 70 m efficiency savings. 👉 Read more

Vir Biotechnology (NASDAQ: VIR) posted Q3 revenue of only ~US$ 240 k (vs ~US$ 2.1 m expected) but emphasized late-stage progress in its HDV Phase 3 ECLIPSE 1 and early oncology programs. Shares rose ~2.9 % intraday before easing 1.5 % after hours. 👉 Read more

Halozyme Therapeutics (NASDAQ: HALO) announced plans for US$ 1.3 b in convertible senior notes due 2031 and 2032 to refinance debt and strengthen liquidity. 👉 Read more

Braveheart Bio raised US$ 185 m Series A from a16z Bio + Health, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences to advance gene-therapy programs in cardiovascular disease. 👉 Read more

Vir Biotech advanced its T-cell engager oncology pipeline to Phase 1 and maintained solid cash reserves (US$ 810.7 m) despite limited revenue. 👉 Read more

Braveheart Bio’s financing highlights renewed investor interest in gene-therapy and rare-cardiovascular indications. 👉 Read more

Bio-Techne’s reagent and diagnostics softness suggests academic and discovery research budgets remain tight.

Vir Biotech’s progress in HDV Phase 3 ECLIPSE 1 and oncology TCE programs underscores continued innovation despite short-term revenue challenges.

Charles River’s raised outlook reinforces early stabilization across preclinical services.

Halozyme’s planned US$ 1.3 b note issuance signals that capital markets remain open to well-capitalized biotechs.

Evommune’s NYSE debut tomorrow will provide a barometer for new-issue sentiment in the immunology space. 👉 Read more

No major regulatory or policy moves reported today. However, continued monetary easing and stable FDA leadership are boosting sector sentiment.

UK policy watchers expect new R&D tax-credit proposals next week, following earlier industry concerns about competitiveness.

Trend 1: Service-provider strength leads the recovery (Charles River).

Trend 2: Research-tool headwinds persist (Bio-Techne).

Trend 3: Late-stage capital accessible for credit-worthy firms (Halozyme).

Trend 4: Venture/IPO capital returns, but selectively (Braveheart Bio, Evommune).

Trend 5: Pipeline resilience remains core to valuation (Vir Biotech).

Bio-Techne Q1 FY2026 sales: US$ 286.6 m (-1 %)

Charles River 2025 EPS guidance: US$ 10.10–10.30

Halozyme convertible offering: US$ 1.3 b proposed

Braveheart Bio Series A: US$ 185 m

Vir Biotech cash: US$ 810.7 m

Zimmer Biomet Holdings (NYSE: ZBH) missed Q3 sales estimates but maintained 2025 guidance; orthopedic reconstruction volume held steady amid pricing pressure.

Xtant Medical Holdings (NASDAQ: XTNT) launched CollagenX™, a collagen-based graft for surgical and trauma wound closure, marking its first major launch since 2023 restructuring.

Eli Lilly & Co. (NYSE: LLY) is set to announce Thursday a weight-loss-drug price reduction following meetings with President Trump, a move that could pressure competitors (Novo Nordisk, Pfizer) on obesity-drug pricing strategies. 👉 Read more

Regulatory focus continues on FDA’s accelerated-approval criteria post-Sarepta/uniQure reviews.

Evommune (EVMN) NYSE debut (expected Nov 6).

Halozyme may finalize convertible-note pricing.

Monitor follow-through in CRL, TECH, and VIR shares as investors digest earnings.

SPDR S&P Biotech ETF (XBI): ~+22 % YTD (vs S&P 500 +15 %) — reflecting selective optimism.

10-Year U.S. Treasury: 4.10 %, down 40 bps since September — providing cost-of-capital relief.

VIX (volatility index): steady ~19.

Overall tone: biotech resilience holds as macro tailwinds ease funding stress and volatility stabilizes.